^
    Back
    Association details:
    Biomarker:GOPC-ROS1 G2032
    Cancer:Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    ASCO 2018
    Title:

    Mutation profiling and treatment choosing of Chinese ROS1 positive advanced lung cancer patients.

    Published date:
    05/16/2018
    Excerpt:
    One patient with GOPC-ROS1 fusion accepted Crizotinib as first-line therapy for 19 months, and disease progressed due to ROS1 G2032 mutation, passed away after 3 months with Cabozantinib….the major therapy choice of Chinese ROS1+ advanced lung cancer patients.